{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"42"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"59"}],"units":"Participants"}],"description":"-To evaluate the overall response (ORR) of ibrutinib in combination with carfilzomib and dexamethasone.","groups":[{"description":"Ibrutinib PO 560 mg + Carfilzomib IV 20/27 mg/m2\n\nIbrutinib\n\nCarfilzomib","id":"OG000","title":"Cohort 1 (560 mg)"},{"description":"Ibrutinib PO 560 mg + Carfilzomib IV 20/36 mg/m2\n\nIbrutinib\n\nCarfilzomib","id":"OG001","title":"Cohort 2a (560 mg)"},{"description":"Ibrutinib PO 560 mg+ Carfilzomib IV 20/36 mg/m2 Dexamethasone PO 20 mg\n\nIbrutinib\n\nCarfilzomib\n\nDexamethasone","id":"OG002","title":"Cohort 2b (560 mg)"},{"description":"Ibrutinib PO 840 mg + Carfilzomib IV 20/36 mg/m2 + Dexamethasone PO 20 mg\n\nIbrutinib\n\nCarfilzomib\n\nDexamethasone","id":"OG003","title":"All RP2D (840 mg)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Please note that the analysis only includes participants who achieved the best response of complete response or partial response from the All-treated population (per protocol).","reportingStatus":"POSTED","timeFrame":"up to 4 years","title":"Overall Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Participants"}